Researchers at a major biomedical lab are using OpenAI's Codex and ChatGPT to search genomic databases for antimicrobial candidates that could combat drug-resistant infections. The approach leverages AI to rapidly screen living and extinct genetic sequences, a process that would take months or years using traditional methods.

The collaboration demonstrates how AI can compress timelines in research and development by automating pattern recognition across massive datasets. The resulting candidates are being validated through conventional laboratory testing.

What This Means for Your Business

Pharmaceutical and biotech companies should explore partnerships with AI vendors to accelerate target discovery and screening phases of drug development. This could significantly reduce time-to-candidate and overall R&D costs. However, ensure that AI-generated candidates undergo rigorous validation and that intellectual property ownership is clearly defined in vendor agreements.